Trial Now Recruiting: A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy (NCT07127978)
WHY IT MATTERS
This real-world study will show how givinostat actually performs in everyday clinical practice for DMD patients in the US, providing practical safety and effectiveness data beyond what controlled trials reveal.
Researchers are looking for 300 patients with Duchenne muscular dystrophy (DMD) to join a study about a medicine called givinostat. The study will track how safe the medicine is and how well it works for patients who are just starting to take it or have been taking it for less than 6 months. Patients will be followed for at least 2 years, with some being tracked for up to 5 years total.
NCT ID: NCT07127978 Status: RECRUITING Conditions: Duchene Muscular Dystrophy Enrollment: 300 Sponsor: ITF Therapeutics LLC Summary: This is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 years for the first enrolled patients, including a 24-month enrollment period and a minimum of 2 years of follow-up.
YOU CAN ACT ON THIS
If you have DMD and are newly starting givinostat or started within the last 6 months, ask your neurologist if you're eligible to enroll in this 300-patient study (NCT07127978) being conducted across US clinical sites.